StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$23.22−1.08 (-4.44%)

Close on Nov 20, 2026Market cap $1.44BP/E 5.8Yield 0.00%

Damora Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Damora Therapeutics's free cash flow for the twelve months ending Dec 31, 2022 was -$43.13M. For fiscal 2022 it was -$43.13M.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$43.13M–
FY2021Dec 31, 2021-$52.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$11.49M–
Q3 FY2022Sep 30, 2022-$9.99M–
Q2 FY2022Jun 30, 2022-$14.81M–
Q1 FY2022Mar 31, 2022-$6.84M–
Q4 FY2021Dec 31, 2021-$17.83M–
Q3 FY2021Sep 30, 2021-$9.21M–
Q2 FY2021Jun 30, 2021-$11.28M–
Q1 FY2021Mar 31, 2021-$14.22M–

More Damora Therapeutics figures

See a number that looks wrong?